Loading
Hawkins Inc Stock: price and insider trades · United States
2 insiders bought €224k of shares over the last 90 days, the latest filed 31 Aug 2026.
Hawkins Inc: what insiders have been doing
Hawkins Inc, classified in the Chemicals & Materials sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, the company's managers filed 27 filings, from 15 insiders.
Only purchases show up on the open market, 4 purchases in all worth €562k, filed by 4 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 3 senior executives and 1 finance chief. One trade stands out by size: a purchase of €174k from Grahek Drew M., disclosed on 5 November 2025.
Within a 30-day window, 1 purchase overlapped with buying by a second insider. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last purchase on record was published on 31 August 2026, which is 47 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 27 filings, this issuer sits above that mark. The full history, which starts in 2021, counts 9 purchases against no sales. The 10-K for the year ended 29 March 2026 shows 1.08 bn USD of revenue and 81.5 m USD of net income and a dividend of 0.75 USD per share.
In the same sector, recent insider purchases at Culp Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
139
Thresholds
n/a
Buy Volume
€1M
9 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleDouglas A. Lange1 buy
Drew M. Grahek1 buy
James A. Faulconbridge1 buy
Jeffrey P. Oldenkamp1 buy
Since the insiders bought
- +5.7%Entry US$124.58 · Close 16 Oct 2026 US$131.66
- +9.4%Entry US$120.35 · Close 16 Oct 2026 US$131.66
- +18.8%Entry US$140.71 · Close at T+90 US$167.16
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Hawkins Inc Buy (bullish), based on 4 analysts. Average price target: US$174.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 12,075 of 24,148 companies
51.5
score / 100
Value46
Quality58
FCF yld3.1%
Earn yld3.0%
EV/EBITDA17.2x
ROE16%
Gross mgn23%
Net mgn7.5%
Debt/EBITDA1.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
US$131.82
Analyst consensus
4 analystsBuy
US$141.00Target US$174.00(+32%)US$200.00
Income statement
RevenueUS$1.1B
Gross profitUS$245.1M23% margin
EBITDAUS$175.4M16% margin
Net incomeUS$81.5M7.3% margin
Valuation
PER (trailing)34.2x
PER (forward)28.2x
P/Book5.0x
Beta0.74
Balance sheet & cash
Market capUS$2.8B
Total debtUS$261.5M
Free Cash FlowUS$86.1M
Debt / Equity47%
Profitability & ownership
ROE15.6%
ROA7.0%
% insiders4.2%
% institutions79.3%
Last declaration on 31 August 2026
Declarations139 total
1,290 shares@ US$119.000.0057% mcap5.5% of flowCommon StockSEC:0001626669-26-000006:0
Canonical exit: 25 Nov 2026 (T+90)
910 shares@ US$118.75360.0040% mcap8.1% of flowCommon StockSEC:0001816092-26-000006:0
Canonical exit: 23 Nov 2026 (T+90)
580 shares0Common StockSEC:0001488673-26-000008:0
721 shares0Common StockSEC:0001380907-26-000004:0
721 shares0Common StockSEC:0001671232-26-000002:0
721 shares0Common StockSEC:0001186351-26-000002:0
721 shares0Common StockSEC:0001301454-26-000002:0
721 shares0Common StockSEC:0001561501-26-000002:0
721 shares0Common StockSEC:0001666284-26-000002:0
16,934 shares0Common StockSEC:0001488673-26-000006:0
8,435 shares0Common StockSEC:0001626669-26-000004:0
2,697 shares0Common StockSEC:0001753076-26-000004:0
1,994 shares0Common StockSEC:0001816092-26-000004:0
1,906 shares0Common StockSEC:0001866740-26-000004:0
1,970 shares0Common StockSEC:0002067498-26-000002:0
3,608 shares@ US$151.620.022% mcap38.5% of flowCommon StockSEC:0001776928-26-000002:0
3,818 shares@ US$151.6231.2% of flowCommon StockSEC:0001753076-26-000002:0
3,493 shares@ US$151.6252.9% of flowCommon StockSEC:0001866740-26-000002:0
10,950 shares@ US$151.6232.0% of flowCommon StockSEC:0001488673-26-000004:0
5,675 shares@ US$151.6231.3% of flowCommon StockSEC:0001626669-26-000002:0
3,855 shares@ US$151.6244.9% of flowCommon StockSEC:0001816092-26-000002:0
1,040 shares0Common StockSEC:0001488673-26-000002:0
1,500 shares@ US$129.2928.9% of flowCommon StockSEC:0001380907-26-000002:0
Canonical exit: 5 May 2026 (T+90)
1,460 shares@ US$126.34259.8% of flowCommon StockSEC:0001753076-25-000007:0
25 of 139 declarations
About Hawkins Inc
Hawkins, Inc. (ticker HWKN) is a U.S.-listed company quoted on Nasdaq in the United States. It operates in the specialty chemicals and water treatment space, with a business model centered on formulation, manufacturing, distribution, and blending of value-added products. Founded in 1938, Hawkins has evolved from a chemical distributor into a diversified industrial solutions provider. The company is headquartered in Roseville, Minnesota, which remains its operational anchor while supporting a broad national footprint.
Hawkins’ reporting structure is built around three core segments: Water Treatment, Food & Health Sciences, and Industrial Solutions. Water Treatment is the company’s most strategically important platform and serves municipal and industrial customers with chemicals, equipment, and technical services. This segment has expanded through targeted tuck-in acquisitions and has become a major driver of growth. In 2025, Hawkins completed the acquisition of WaterSurplus, a transaction that meaningfully broadened the company’s water-treatment capabilities, including membrane systems, engineering and design services, filtration media, equipment rental and manufacturing, and rapid-response PFAS-related solutions. Food & Health Sciences focuses on ingredients used in nutrition, dietary supplements, excipients, botanicals, sweeteners, enzymes, and other health-oriented applications. Industrial Solutions provides chemical products and application support for manufacturing and process industries.
Read moreShow less
From a competitive standpoint, Hawkins positions itself as a service-intensive, technically oriented supplier rather than a commodity-only distributor. Management has emphasized customer support, customized applications, and local execution. The competitive landscape is fragmented: the company has stated that no single competitor dominates all of the markets it serves, although many rivals are larger and may have greater financial resources. Hawkins’ nationwide network of facilities across the United States strengthens its logistics, technical service, and customer proximity, which is particularly important in regulated end markets such as water treatment.
Recent developments underscore a clear growth narrative. Hawkins reported record fiscal 2025 revenue of $974.4 million and indicated that revenue is expected to surpass $1 billion in fiscal 2026, a symbolic milestone for a company founded 86 years ago. The company has also remained active on the acquisition front, including WaterSurplus, StillWaters Technology, and Redbird Chemical, reinforcing its presence in the southern United States and deepening its higher-margin offering mix. For French-speaking investors, HWKN stands out as a niche industrial compounder with exposure to water infrastructure, specialty ingredients, and a disciplined acquisition strategy. The combination of steady end-market demand, technical differentiation, and ongoing M&A integration is central to the investment case.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
